A better way to LIMS: biology's modern solution

Legacy LIMS are overly rigid, costly, onerous to maintain, and built for chemistry, not modern biology. Outdated LIMS solutions cannot efficiently support the complexity of managing R&D for cell and gene therapies, antibody-drug conjugates, and RNA therapeutics. These modalities require advanced, built-for-biology software to process, analyze, and scale novel biomolecules into marketable products.